Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations

Csanády, László and Törőcsik, Beáta (2019) Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations. ELIFE, 8. pp. 1-18. ISSN 2050-084X

Preview

Text 30775333_Cystic_fibrosis_drug_ivacaftor_eLIFE_2019.pdf Download (1MB) | Preview

Abstract

The devastating inherited disease cystic fibrosis (CF) is caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) anion channel. The recent approval of the CFTR potentiator drug ivacaftor (Vx-770) for the treatment of CF patients has marked the advent of causative CF therapy. Currently, thousands of patients are being treated with the drug, and its molecular mechanism of action is under intensive investigation. Here we determine the solubility profile and true stimulatory potency of Vx-770 towards wild-type (WT) and mutant human CFTR channels in cell-free patches of membrane. We find that its aqueous solubility is ~200 fold lower (~60 nanomolar), whereas the potency of its stimulatory effect is >100 fold higher, than reported, and is unexpectedly fully reversible. Strong, but greatly delayed, channel activation by picomolar Vx-770 identifies multiple sequential slow steps in the activation pathway. These findings provide solid guidelines for the design of in vitro studies using Vx-770. © 2019, Csanády and Töröcsik.

Actions (login required)

Edit Item